YS Biopharma Co., Ltd. - Pangali EV/EBITDA LSB

This EV/EBITDA chart for LakeShore Biopharma Co. (LSB) helps assess the expansion of the Chinese leader in anti-rabies vaccines, which is penetrating the infectious disease protection market via mRNA technologies. The current metric stands at . Despite a liquidity shortage driven by costly research, the business relies on patents that ensure global distribution of drugs with low unit economics.

LakeShore Biopharma Co., Ltd. - Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan LSB (periode 04.07.2022 - 11.11.2026)

Rincian analitis perusahaan ysbiopharm.com (LSB)

- rega pasar lan target rega analis:

Bagan rega YS Biopharma|LSB - Prakiraan gabungan firma investasi

- rincian nilai pasar emiten:

Kapitalisasi pasar LSB|LSB - Nilai Wutuh Bisnis

- statistik nilai buku emiten:

Nilai Buku saben Saham LakeShore Biopharma|LSB - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku ysbiopharm.com|LSB - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Total Utang marang Ekuitas LakeShore Biopharma Co.|LSB - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal LakeShore Biopharma|LSB - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku LSB|LSB - Utang jangka dawa|Utang jangka cendhak perusahaan LakeShore Biopharma|Likuiditas cepet ysbiopharm.com

- rincian asil keuangan lan kelipatan valuasi:

LSB - Asil keuangan resik|Bathi sing dikarepake LakeShore Biopharma Co.|LSB - Rasio rega marang bathi|Pangali Forward P/E LakeShore Biopharma Co.|LSB - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan LSB|LSB - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) LakeShore Biopharma|LSB - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan ysbiopharm.com|LSB - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep LakeShore Biopharma Co.

Analisis komprehensif perusahaan:LSB (YS Biopharma)

Professional managers utilize fundamental filters to assess the value of assets with high debt loads and significant tax liabilities. This metric compares the total enterprise value to operating profit, which is critical for LakeShore Biopharma Co. (LSB) given its capital-intensive bio-plants and government tenders; analyzing the company's current EV/EBITDA ratio allows for the identification of a discounted entry point, avoiding value traps.

Analisis pesaing